Highest-materiality recent filing
My Size (MYSZ) gets Nasdaq notice: equity $2.347M below $2.5M minimum
Received Nasdaq letter Aug 25, 2026; stockholders' equity $2.347M as of Jun 30, 2026 vs $2.5M minimum.
MySize Q2 revenue up 53% to $3.07M; net loss widens to $1.75M
Revenue $3.07M, +53% YoY; H1 revenue $5.46M, +57% YoY.
MySize completes 1-for-8 reverse stock split to regain Nasdaq bid-price compliance
Reverse split effective 4:30 p.m. ET on Aug 12, 2026; split-adjusted trading begins Aug 13 on Nasdaq under symbol MYSZ.
My Size enters $10M equity purchase agreement with Square Gate Capital
Up to $10M of common stock can be sold to Square Gate Capital over 36 months at 96.5% of lowest VWAP (regular puts) or 100% of lowest intraday price (intraday puts).
My Size shareholders approve reverse stock split authorization; blank check preferred fails
Elected Oron Branitzky and Guy Zimmerman as Class II directors with 1,072,235 and 1,071,940 votes for, respectively.
MySize Q1 revenue up 62% to $2.39M; gross margin expands to 39.3%, net loss widens to $1.48M
Revenue increased 62% YoY to $2.39 million; gross profit up 124% to $940,000.
MySize receives Nasdaq bid price deficiency notice; reports preliminary 2025 revenue ~$10M
Nasdaq notified MySize on March 2, 2026 that its common stock bid price closed below $1.00 for 30 consecutive days; 180-day cure period until August 31, 2026.
My Size receives Nasdaq delisting notice for bid price below $1.00; has until Aug 31, 2026 to cure
Nasdaq notified My Size on March 2, 2026 that bid price was below $1.00 for 30 consecutive trading days.
MySize expects FY2025 revenue ~$10M, ~$4M cash; targets ~$15M in 2026
Preliminary FY2025 revenue of approximately $10 million; estimated cash balance of $4 million at year-end.
My Size awards 400,000 restricted shares to execs; CEO Luzon receives 200,000
Compensation Committee approved restricted stock awards (RSAs) on Dec 15, 2025, under the 2017 Equity Incentive Plan.
MySize Q3 2025 revenue $2.6M, up 26% sequentially; net loss narrows to $2.8M
Revenue of $2.6 million, up 26% sequentially from Q2 2025.
My Size acquires ShoeSize.Me for $440K (cash+stock) plus warrant; adds AI footwear sizing
Acquired ShoeSize.Me AG for $150K cash, 241,093 shares (~$290K), and a 28K-share milestone warrant.
My Size shareholders approve equity plan amendment and elect directors at 2025 annual meeting
Shareholders elected Arik Kaufman and Roy Golan as Class I directors for three-year terms.
MySize Q2 revenue $2.0M (+2% YoY); operating loss narrows 49%; Percentil adds $180k
Q2 revenue $2.0M (+2% YoY); H1 revenue $3.5M (-30% YoY) on Orgad market decline.
My Size reprices employee options to $1.28; accelerates vesting for 18,750 shares for former CFO
Compensation Committee reduced exercise price of 13,926 shares from $3.832–$8.72 to $1.28, the June 4 closing price.
MySize acquires Percentil assets for ~$679k; expects $1.5M revenue in H2 2025
Acquired production unit of Casi Nuevo Kids (Percentil) for €610,807 (~$679k) in cash and assumed liabilities.
My Size FY 2024 revenue up 18% to $8.26M, cash more than doubles to $4.88M
Revenue $8.26M (+18% YoY); net loss narrowed 37% to $3.99M.
My Size announces CFO resignation, appoints Oren Elmaliah as new CFO and Roy Golan to board
CFO Or Kles resigned effective March 31, 2025 (previously disclosed).
My Size enters ATM equity offering with H.C. Wainwright for up to $4.1M
Entered into an at-the-market offering agreement with H.C. Wainwright to sell up to $4.1 million of common stock.
My Size CFO Or Kles resigns effective March 31, 2025; search underway
Or Kles notified My Size on January 14, 2025 of his resignation as CFO.
My Size shareholders elect Ronen Luzon as Class III director, ratify accountant at annual meeting
Stockholders elected Ronen Luzon as Class III director with 298,026 votes for, 4,830 against, 2,600 abstentions, excluding 321,356 broker non-votes.
My Size raises ~$3.0M from warrant exercise of 653,028 shares
653,028 warrants from the May 2024 repricing were exercised on Dec 27, 2024.
MySize preliminary 2024 revenue $8.5M (+23% YoY), targets $15M for 2025
Preliminary 2024 revenue of $8.5M, up 23% YoY; project $15M revenue in 2025 based on current conditions.
MySize Q2 revenue up 53% to $1.97M, net loss narrows 25% to $964K
Revenue of $1.97M (+53% YoY) driven by Orgad growth and Naiz Fit SaaS revenue.
My Size raises ~$3.26M via warrant exercise inducement; issues new warrants for up to 1.34M shares
Holder exercises 670,989 existing warrants at reduced price of $4.86/share; gross proceeds ~$3.26M.
MySize Q1 revenue jumps 314% to $2.98M; net loss narrows 61% to $1.02M
Revenue $2.98M (+314% YoY); SaaS revenue $177K (+25%).
My Size regains Nasdaq compliance; bid price above $1.00 for 10 days
Nasdaq confirmed My Size regained compliance with Listing Rule 5550(a)(2) on May 7, 2024.
My Size approves 1-for-8 reverse stock split to maintain Nasdaq listing
Stockholders approved reverse split authority at April 15 special meeting; vote was 1.73M for, 0.72M against.
My Size grants 600,000 restricted shares to three officers; CEO Luzon receives 300k
CEO Ronen Luzon receives 300,000 restricted shares; Or Kles and Billy Pardo each receive 150,000.
My Size receives TASE delisting confirmation; last trade March 27, effective March 31, 2024
Shareholders approved voluntary delisting from Tel Aviv Stock Exchange on December 27, 2023.
My Size shareholders approve equity plan increase and Tel Aviv Stock Exchange delisting
Approved amendment to 2017 Equity Plan to increase reserved shares from 289,000 to 1,040,000.
My Size Q3 revenue up 197% to $2.16M; loss narrows 44%; reiterates $8M FY guidance
Q3 revenue $2.16M, up 197% YoY, driven by Orgad and Naiz Fit SaaS; gross margin 64%.
My Size receives Nasdaq notice for non-compliance with $1.00 minimum bid price
Notification received Nov 3, 2023; bid price below $1.00 for 30 consecutive business days.
My Size enters inducement agreement for $4.2M warrant exercise and new warrant issuance
Holder exercises 2,018,012 existing warrants at reduced $2.09/share; gross proceeds approx. $4.2M.
MySize Q2 revenue up 61% to $1.29M, net loss narrows 25% to $1.291M
Consolidated revenue $1.29M (+61% YoY); gross profit $519K (+61%); gross margin stable at 40%.
My Size reduces exercise price of executive options to $1.09 from $26.00
Compensation Committee repriced 23,575 options held by officers and directors to $1.09/share, the July 13 closing price.
My Size Q1 revenue up 78% to $720k; net loss widens to $2.65M on fire-related write-down
Revenue $720k (+78% YoY); SaaS revenue from MySizeID/Naiz Fit up 223% to $142k.
MySize meets 2022 revenue guidance of $4.5M; expects 2023 revenue to double
Consolidated revenue $4,459,000, up 3,304% YoY; Q4 revenue ~$2.5M.
My Size raises $3.0M in registered direct offering and PIPE priced at $3.055/share
Gross proceeds ~$3.0M from combined offering of common shares, pre-funded warrants, and Series A/B warrants.
My Size files Amendment No. 2 to 8-K to add auditor consent for Naiz acquisition
Filing solely corrects omission of signed consent from independent auditor Airen Auditores SLP.
My Size subsidiary Orgad warehouse fire; sales impact not expected
Fire at Orgad warehouse in Israel on Jan 2, 2023; no casualties or injuries reported.
My Size completes Naiz acquisition; Naiz 2021 revenue $248K, net profit $82K
Acquisition of Naiz Bespoke Technologies closed Oct 11, 2022; this 8-K/A adds required audited and unaudited financials.
My Size regains Nasdaq minimum bid price compliance
Nasdaq notified My Size that closing bid price was >=$1.00 for 10 consecutive business days through Dec 22, 2022.
My Size (MYSZ) announces 1-for-25 reverse stock split effective Dec 8, 2022
Board approved 1-for-25 reverse stock split; effective after market close Dec 8, 2022.
MySize Q3 revenue surges 2242% to $726K on Orgad acquisition; net loss $2.0M
Revenue of $726K vs $31K YoY; Orgad contributed $685K in Q3.
My Size acquires Naiz Fit for $500k cash + 6M shares; expects $1M additional revenue in 2023
Acquired Spain-based Naiz Fit (SaaS sizing tech) for $500k initial cash, 6M shares (~19.9% of MYSZ), plus up to $1.55M in milestone cash.
My Size grants 4.4M restricted shares to five executives under 2017 plan
CEO Ronen Luzon receives 2.5M restricted shares; four other officers get 600K, 600K, 400K, 300K shares respectively.
MySize reports Q2 revenue up 2570% to $801K; net loss narrows 60%
Revenue of $801K vs $30K YoY, driven by Orgad acquisition ($752K from Orgad).
My Size granted Nasdaq extension until Jan 2, 2023; revenue guidance $5M for FY2022
Nasdaq granted My Size 180-day extension to Jan 2, 2023 to meet $1 minimum bid price.
MySize Q1 revenue jumps 1400% to $404K on Orgad acquisition; reaffirms FY2022 guidance of $5M+
Revenue $404K (+1400% YoY); gross profit $153K (37.9% margin), vs $27K prior year.
As previously disclosed, Or Kles, the Chief Financial Officer of My Size, Inc. (the “Company”) resigned effective March 31, 2025.
On March 6, 2025, the Company appointed Oren Elmaliah as the Company’s Chief Financial Officer, effective April 1, 2025 to replace Mr. Kles.
Mr. Golan was additionally appointed to the Audit Committee as chair, the Compensation Committee, and Nominating and Corporate Governance Committee.
on March 6, 2025, the Company’s board of directors appointed Roy Golan as a Class I director to replace Mr. Elmaliah, effective immediately.
As a then member of the board of directors of the Company, Mr. Elmaliah stepped down as a member of the board and all committees of the board of directors of the Company.
On January 14, 2025, Or Kles, Chief Financial Officer of My Size, Inc. (the “Company”), notified the Company of his decision to resign as the Company’s CFO, to be effective March 31, 2025.
On January 30, 2022, My Size, Inc. (the “Company”), appointed Ezequiel Javier Brandwain to serve as the Company’s Chief Commercial Officer, effective as of February 1, 2022.
Max materiality 0.75 · Median 0.65 · Most common event other_material